Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2002-01-25
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.3s-guojian.com
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
Phase 2
Recruiting
- Conditions
- First-line Advanced NSCLC Patients
- Interventions
- Drug: Paclitaxel-albuminDrug: PD-1/L1
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 235
- Registration Number
- NCT06412471
- Locations
- 🇨🇳
Institute of The Hunan Cancer Hospital, Changsha, China
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced, Recurrent or Metastatic Malignancies
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-10-18
- Target Recruit Count
- 180
- Registration Number
- NCT06390774
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 120
- Registration Number
- NCT06361927
- Locations
- 🇨🇳
The Hunan Cancer Hospital, Changsha, Hunan, China
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
Phase 1
Not yet recruiting
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-22
- Target Recruit Count
- 104
- Registration Number
- NCT06324812
Efficacy and Safety Study of 610 in Patients With Severe Asthma
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Target Recruit Count
- 480
- Registration Number
- NCT06323213
An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO
Phase 3
Not yet recruiting
- Conditions
- Plaque Psoriasis Patients
- Interventions
- Drug: 608 Q2WDrug: 608 Q4W
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 750
- Registration Number
- NCT06299982
A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.
Phase 2
Active, not recruiting
- Conditions
- Gout Arthritis
- Interventions
- Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mgDrug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-08-05
- Target Recruit Count
- 157
- Registration Number
- NCT06270225
- Locations
- 🇨🇳
Shanghai Huashan Hospital Fudan University-Rheumatology, Shanghai, Shanghai, China
A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)
Phase 2
Active, not recruiting
- Conditions
- Ankylosing Spondylitis
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-10-23
- Target Recruit Count
- 250
- Registration Number
- NCT06242652
- Locations
- 🇨🇳
Site 01, Beijing, Beijing, China
A Study to Evaluate 608 in Patients with Non- Radiographic Axial Spondyloarthritis (nr-axSpA)
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-03-11
- Target Recruit Count
- 180
- Registration Number
- NCT06222671
- Locations
- 🇨🇳
Site 01, Beijing, Beijing, China
🇨🇳Site 03, Beijing, Beijing, China
🇨🇳Site 05, Chongqing, Chongqing, China
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 510
- Registration Number
- NCT06173284
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, China
🇨🇳Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China